$XBI $92.43 | -0.96%
Covid Updates
$
Pipeline Updates
$MNOV +3.9% MediciNova Announces Secondary Analysis of Phase 2 Trial of MN-166 (ibudilast) in Alcohol Use Disorder Published in Alcoholism: Clinical and Experimental Research source
$VYNE +9.5% VYNE Therapeutics Announces Positive Phase 1b Efficacy Data for FMX114 from Phase 1b/2a Trial for the Treatment of Mild-to-Moderate Atopic Dermatitis source
$NERV -3.8% Minerva Neurosciences Provides Update from Type C Meeting with FDA and Next Steps in Preparation for Submission of a New Drug Application (NDA) for Roluperidone for the Treatment of Negative Symptoms in Schizophrenia source
$ARDX -1.9% Ardelyx Presents Positive Data Further Supporting Efficacy and Safety of XPHOZAH® (tenapanor) at National Kidney Foundation 2022 Spring Clinical Meetings source
$TNXP +4.0% Tonix Pharmaceuticals Initiates Enrollment in the RESILIENT Study, a Potentially Pivotal Phase 3 Study of TNX-102 SL for the Management of Fibromyalgia source
$ALKS +0.3% Alkermes Presents New Data From Psychiatry Portfolio at 2022 Congress of the Schizophrenia International Research Society source
$APTX -49.2% Aptinyx Reports Results from Phase 2b Study of NYX-2925 in Painful Diabetic Peripheral Neuropathy source
$ANNX -5.3% ANNEXON BIOSCIENCES COMPLETES ENROLLMENT IN ARCHER PHASE 2 TRIAL OF NOVEL C1Q INHIBITOR, ANX007, IN PATIENTS WITH GEOGRAPHIC ATROPHY source
Business Updates
$MRNA +2.8% IAVI and Moderna Partner to Tackle Broad Global Health Priorities Using mRNA for Vaccines and Antibodies source
Posted by JM
Comments